#Switzerland #Cerbios-Pharma #HAS Healthcare #65 Equity Partners #Biasca

HAS Healthcare and Cerbios-Pharma: A New Era for the CDMO Industry

In a significant development in the pharmaceutical industry, HAS Healthcare Advanced Synthesis SA (HAS) has announced its acquisition of Cerbios-Pharma SA. This strategic move aims to forge a leading international player in the Contract Development and Manufacturing Organization (CDMO) sector. With robust backing from 65 Equity Partners, this acquisition is set to reshape the landscape of pharmaceutical manufacturing.

Creating a Combined Force

The acquisition, based in the picturesque region of Ticino, Switzerland, allows HAS and Cerbios to pool their extensive production capabilities, chemical and biological expertise, and advanced technology. Together, the two companies are looking to create new growth opportunities, enhancing their positions in the ever-evolving pharmaceutical market. Under this union, they aspire to meet the burgeoning demand for complex therapies, thereby positioning themselves as a cornerstone of innovation within the industry.

According to Riccardo Braglia, CEO of 3B Future Holding SA and board member of HAS, this merger represents a critical milestone in their global expansion strategy. The merger is billed as an opportunity to leverage complementary skills and resources, which will, in turn, enable them to offer innovative, high-quality, tailored solutions to clients.

Supported by 65 Equity Partners

This acquisition is significantly supported by 65 Equity Partners, an international investment firm known for nurturing family-owned businesses and entrepreneurs. As part of this transaction, they will hold approximately 40% of the new entity's shares alongside the Braglia family, who will retain majority ownership. This collaborative effort with 65 Equity Partners underscores a commitment to innovation and long-term growth for both companies.

Pascal Heberling, Partner and Co-Head of Europe at 65 Equity Partners, noted the strategic importance of this merger at a time when the pharmaceutical sector is experiencing robust structural growth drivers. He emphasized the increasing demand for advanced therapies, as well as scientific breakthroughs, making this an opportune moment for such a partnership.

A Commitment to Excellence

Both HAS and Cerbios are guided by strong corporate cultures and values that prioritize long-term commitments to their communities and the industry. The new group is poised to create a significant impact, not only as a top-tier CDMO but also as a pivotal player in advancing healthcare solutions globally. The merger combines over 400 skilled employees dedicated to innovation and quality, ensuring that both companies continue to thrive in a competitive environment.

The operational aspects of the acquisition are expected to be smooth, as both organizations are compliant with international regulations and standards, bolstered by their long-standing reputations within the pharmaceutical sector. Regular inspections from regulatory authorities such as SwissMedic and the FDA further position them as trustworthy partners in the industry.

Looking Ahead

In the coming months, the focus will be on integrating services and expanding the collaborative efforts between HAS and Cerbios. This merger will enable both companies to cater to diverse therapeutic areas, including oncology, neurology, and rare diseases. As outlined in the transaction agreements, the integration will reflect the shared vision to innovate, expand, and maintain excellence in all offerings.
The collaborative future of HAS Healthcare and Cerbios-Pharma promises not only growth for the companies but also enhanced healthcare solutions for a global market increasingly seeking innovative pharmaceutical developments.

In conclusion, the merging of HAS and Cerbios represents more than just a business acquisition; it stands to reshape the pharmaceutical landscape, paving the way for groundbreaking advancements in drug development and manufacturing,
creating a legacy that will last for decades. This strategic alliance, fostered through commitment and expertise, is set to thrive in the complex and ever-changing world of healthcare.